World Heart Corp said it received a conditional approval from U.S. health regulators to begin a clinical study of its magnetically levitated implantable heart pump, sending its shares up as much as 60 percent.
The study of the company's Levacor ventricular assist device has been assigned a CMS category B2 status, which makes insurance reimbursement possible
The U.S. Food and Drug Administration has asked the company to submit additional data within 45 days, but permitted the study to begin on getting approvals from the Institutional Review Board, the company said in a statement.
About Stock Einstein
StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Disclaimer: Full disclaimer at http://StockEinsteain.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinsteain, nor any of its affiliates are registered investment advisors or broker dealers.
